Description

Simple

Clinical

Overview

MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.

Pharmacology

Indication

Investigated for use/treatment in solid tumors.

Pharmacodynamic

Information currently not available.

Mechanism of action

The already approved and accepted therapy of anti-angiogenesis (suppressing tumor vascularization), is complemented by MBT-0312. An innovative proprietary carrier system of lipid complexes facilitates a novel application method of established cytostatic drugs (e.g. Taxane), intended to cause specifi... Read more

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with MBT-0312
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)